Safety study of ArtiSential during rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial checks whether a tool called ArtiSential can be used safely and practically during planned rectal cancer operations. It may help the surgical team prepare and perform the operation more smoothly, but the main goal is safety and feasibility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- Your diagnosis is confirmed by biopsy (proven adenocarcinoma)
- Your cancer is rectal cancer or at the rectosigmoid junction
- Your cancer has not spread to distant places (no metastasis at diagnosis)
- Your surgery is planned to cure the cancer (not palliative) and is not an emergency
- Your operation plans include a low anterior resection using the double-stapled technique
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an artificial-intelligence support tool that helps surgeons make decisions during surgery for rectal cancer. If you qualify, the tool may be used alongside the surgical team to support safer, more effective care.
This study follows real-world treatment of locally advanced rectal cancer (cancer that has grown into nearby tissues but hasn't spread to distant organs) in patients who receive chemotherapy and/or radiation before surgery. Researchers track how different treatment approaches work to help improve outcomes.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This trial tests a new way of connecting the bowel after removing cancer or precancerous lesions in the sigmoid colon or upper rectum. It is for patients who are having planned, curative surgery and may help reduce complications.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.